23 Spinal Muscular Atrophy Clinical Trials in Birmingham, AL (2026)

Q: How do I join a clinical trial in Birmingham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you.

Recruiting Spinal Muscular Atrophy Studies in Birmingham

NCT04088071Recruiting

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

The primary purpose of this Registry is to assess procedural safety and long-term effectiveness of catheter ablations in the treatment of subjects with PAF, PsAF, and VA. The Registry will utilize rea...

Birmingham, AL20,000 participantsHeart Rhythm Clinical and Research Solutions, LLC

View Study Details

NCT03851445Recruiting

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to ...

Birmingham, ALPHASE210,000 participantsSWOG Cancer Research Network

View Study Details

NCT05236114Recruiting

GEMINI-NSCLC: NSCLC Biomarker Study

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition t...

Birmingham, AL1,200 participantsTempus AI

View Study Details

NCT04928846Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...

Birmingham, ALPHASE3768 participantsAbbVie

View Study Details

NCT05208762Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect i...

Birmingham, ALPHASE1714 participantsSeagen, a wholly owned subsidiary of Pfizer

View Study Details

NCT07144280Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression gr...

Birmingham, ALPHASE3680 participantsPfizer

View Study Details

NCT07190248Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted th...

Birmingham, ALPHASE3675 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06875310Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemothera...

Birmingham, ALPHASE3630 participantsMirati Therapeutics Inc.

View Study Details

NCT06538038Recruiting

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Grow...

Birmingham, AL538 participantsPrECOG, LLC.

View Study Details

NCT07365241Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, a...

Birmingham, ALPHASE3531 participantsAbbVie

View Study Details

NCT05624996Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by ...

Birmingham, ALPHASE3474 participantsNRG Oncology

View Study Details

NCT06343402Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 ...

Birmingham, ALPHASE1350 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT06324201Recruiting

The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.

Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patient...

Birmingham, AL250 participantsHeart Rhythm Clinical and Research Solutions, LLC

View Study Details

NCT05967689Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring...

Birmingham, ALPHASE2220 participantsTaiho Oncology, Inc.

View Study Details

NCT04402788Recruiting

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab ...

Birmingham, ALPHASE2138 participantsNational Cancer Institute (NCI)

View Study Details

NCT07246863Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivoluma...

Birmingham, ALPHASE2131 participantsCatalYm GmbH

View Study Details

NCT06362252Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participan...

Birmingham, ALPHASE1123 participantsDaiichi Sankyo

View Study Details

NCT07098988Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemot...

Birmingham, ALPHASE2107 participantsCatalYm GmbH

View Study Details

NCT05363280Recruiting

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic sma...

Birmingham, ALPHASE280 participantsAdvenchen Pharmaceuticals, LLC.

View Study Details

NCT06841055Recruiting

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy Following Chemoimmunotherapy

This is a Phase II, multisite, open-label, single arm study with two parts in participants with advanced/metastatic NSCLC which progressed after a first-line chemoimmunotherapy. Part 1 is safety run-...

Birmingham, ALPHASE260 participantsBioNTech SE

View Study Details

NCT04616560Recruiting

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Newly Diagnosed, Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly dia...

Birmingham, ALPHASE255 participantsNational Cancer Institute (NCI)

View Study Details

NCT06364917Recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker known as PD-L1. This...

Birmingham, ALPHASE224 participantsUniversity of Alabama at Birmingham

View Study Details

NCT07131696Recruiting

The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage

The significance of developing a safe and effective therapy for aneurysmal subarachnoid hemorrhage (aSAH) patients suffering cerebral vasospasm (CVS) cannot be overstated. Vasospasm - a clamping down ...

Birmingham, ALNA10 participantsMarshall Holland

View Study Details

About Spinal Muscular Atrophy Clinical Trials in Birmingham

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 23 spinal muscular atrophy clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 37,758 participants. Research is being sponsored by Heart Rhythm Clinical and Research Solutions, LLC, SWOG Cancer Research Network, Tempus AI and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Birmingham — FAQ

Are there spinal muscular atrophy clinical trials in Birmingham?

Yes, there are 23 spinal muscular atrophy clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 23 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated August 28, 2026 from ClinicalTrials.gov